Insight Molecular Diagnostics Inc. (IMDX)

Market Cap	92.61M -49.6%
Revenue (ttm)	1.67M -60.8%
Net Income	-49.36M
EPS	-1.46
Shares Out	32.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,478
Open	2.840
Previous Close	2.840
Day's Range	2.760 - 2.921
52-Week Range	2.420 - 8.510
Beta	1.80
Analysts	Buy
Price Target	8.25 (+191.52%)
Est. Earnings	Nov 9, 2026

About IMDX

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2009
• Employees: 58
• Stock Exchange: Nasdaq
• Ticker Symbol: IMDX
• Website: https://www.imdxinc.com

Financial Performance

In 2025, IMDX's revenue was $4.06 million, an increase of 115.58% compared to the previous year's $1.88 million. Losses were -$50.22 million, -17.57% less than in 2024.

Analyst Summary

According to 5 analysts, the average rating for IMDX stock is "Buy." The 12-month stock price target is $8.25, which is an increase of 191.52% from the latest price.

Price Target

$8.25

(191.52% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 24, 2026

Data Sources Report a data error